SCHEDULE 13G/A: LSP 7 Entities Disclose 13.8% Stake in Oculis Holding AG
Beneficial Ownership Report Amendment
LSP 7 Cooperatieve U.A. and LSP 7 Management B.V. have filed an amended Schedule 13G, reporting a shared beneficial ownership of 13.8% in Oculis Holding AG as of December 31, 2024.
Summary
- LSP 7 Cooperatieve U.A. and LSP 7 Management B.V. (collectively, the "Reporting Persons") have filed an Amendment No. 1 to Schedule 13G regarding their beneficial ownership in Oculis Holding AG.
- As of December 31, 2024, the Reporting Persons collectively beneficially own 5,752,894 Ordinary Shares of Oculis Holding AG.
- This ownership represents 13.8% of Oculis Holding AG's Ordinary Shares outstanding.
- The percentage is calculated based on 41,745,295 Ordinary Shares outstanding as of September 6, 2024, as disclosed in Oculis Holding AG's Prospectus on Form 424B3.
- LSP 7 Cooperatieve U.A. is the record holder of the shares, and LSP 7 Management B.V. is its sole director.
- The managing directors of LSP 7 Management B.V., Martijn Kleijwegt, Rene Kuijten, and Joachim Rothe, may be deemed to beneficially own the shares but disclaim beneficial ownership.
Sentiment
Score: 7
Explanation: The sentiment is moderately positive as it confirms a significant and continued investment by a specialized life sciences fund (LSP 7, part of EQT Life Sciences) in Oculis Holding AG, indicating ongoing confidence from a sophisticated investor. While a routine filing, the size of the stake is noteworthy.
Positives
- The filing indicates a significant, continued investment by LSP 7 entities in Oculis Holding AG, demonstrating a long-term commitment to the company.
- The 13.8% stake represents a substantial ownership position, potentially signaling confidence from a specialized life sciences investor.
Negatives
- The document itself does not present any negative financial or operational information about Oculis Holding AG, as it is purely a disclosure of beneficial ownership.
Risks
- The document does not explicitly detail risks related to Oculis Holding AG's operations or financial health; it is a beneficial ownership filing.
Future Outlook
NA
Management Comments
- Martijn Kleijwegt, Rene Kuijten, and Joachim Rothe disclaim beneficial ownership of the shares held of record by LSP 7 Cooperatieve U.A.
Industry Context
This filing reflects a significant stake held by LSP 7 entities, which are part of EQT Life Sciences, a prominent investor in the life sciences sector. Their continued substantial ownership in Oculis Holding AG, a company in the pharmaceutical/biotechnology industry, suggests ongoing strategic interest in the sector and potentially in Oculis's specific therapeutic areas.
Comparison to Industry Standards
- NA
Management Changes
| Role | Previous Person | New Person | Effective Date | Reason |
|---|---|---|---|---|
| NA | NA | NA | NA | The document clarifies the relationship between LSP 7 Cooperatieve U.A. and LSP 7 Management B.V. and its managing directors, but it does not announce changes in Oculis Holding AG's management. |
Corporate Governance
| Change Type | Description | Effective Date | Impact Assessment |
|---|---|---|---|
| NA | The document does not detail changes in Oculis Holding AG's bylaws, committees, policies, or procedures. | NA | NA |
Legal Proceedings
- NA
Related Party Transactions
- NA
Stakeholder Impact
- Shareholders: Provides transparency regarding a significant institutional investor's stake, which can be viewed positively as a vote of confidence.
- Management: Indicates continued oversight and potential influence from a major shareholder.
Next Steps
- NA
Key Dates
| Date | Description |
|---|---|
| 2024-09-06 | Date as of which 41,745,295 Ordinary Shares of Oculis Holding AG were reported outstanding in the Issuer's Prospectus on Form 424B3. |
| 2024-12-31 | Date of event which requires filing of this statement, representing the beneficial ownership as of this date. |
| 2025-02-12 | Date of filing and signature of the Schedule 13G Amendment No. 1. |
Keywords
Oculis Holding AG, LSP 7 Cooperatieve U.A., LSP 7 Management B.V., Schedule 13G, Beneficial Ownership, Ordinary Shares, Equity Stake, SEC Filing, Investment, Life Sciences Investment
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.